Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies

摘要: Objective To systematically review published and unpublished efficacy studies of agomelatine in people with depression. Design Systematic meta-analysis. Data sources Literature search (Pubmed, Embase, Medline), Cochrane Central Register Controlled Trials, European Medicines Agency (EMA) regulatory file for agomelatine, manufacturers (Servier). Eligibility criteria Double blind randomised placebo comparator controlled trials depression standard rating scales. synthesis Studies were pooled by using a random effects model DerSimonian Laird weights comparisons antidepressant. The primary measure (change scale score) was summarised standardised mean difference (SMD; effect size) secondary outcome measures relative risks. All results presented 95% confidence intervals. Statistical heterogeneity explored visual inspection funnel plots the I 2 statistic. Moderators meta-regression. Results We identified 20 7460 participants meeting inclusion (11 literature, four from file, five manufacturer). Almost all used 17 item Hamilton (score 0-50). Agomelatine significantly more effective than an size (SMD) 0.24 (95% interval 0.12 to 0.35) risk response 1.25 (1.11 1.4). Compared other antidepressants, showed equal (SMD 0.00, −0.09 0.10). Significant uncovered most analyses, though bias low. Published likely have that suggested advantages agomelatine. Conclusions is antidepressant similar antidepressants. generally had favourable studies.